November 30th, 2023

 

FORT WORTH, TX. -- AyuVis Research, Inc. has been selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR), at the U.S. Department of Health and Human Services (HHS).

 

In addition, AyuVis has been invited for a virtual residency at JLABS @ TMC, located at the Texas Medical Center in Houston. Participation in these programs will support the expansion of AyuVis’ drug development program and pursuit of additional non-dilutive funding opportunities.

​

“I am very excited for AyuVis’ selection into these programs. The AyuVis team is looking forward to working with industry and government leaders to aid in the continued development of our technologies within the medical fields with the most unmet need,” said Dr. Suchismita Acharya, the Founder and CEO of AyuVis.

​

AyuVis is developing a new generation of immunotherapies, including AVR-48, that provide a well-balanced outcome where mild activation and controlled suppression of the immune system is needed to effectively treat disease. This process allows the drug to control inflammation and infection.

​

Blue Knight is a joint initiative between Johnson & Johnson Innovation - JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, dedicated to the acceleration of transformative technology and science that will enable a swift and targeted response to evolving threats to public health and safety. AyuVis’ technology is aiming to solve the urgent unmet need for non-steroidal, anti-inflammatory therapies and anti-infectives that can circumvent multi-drug resistant infections. AVR-48 has shown to be effective in extensive IND-enabling preclinical research and is ready for clinical trials. 

​

​

About AyuVis Research, Inc. 

​

AyuVis’ first target indication is the prevention of bronchopulmonary dysplasia (BPD), a chronic lung disease in preterm babies where there are no available FDA-approved therapies. Follow-on indications with high unmet medical need include the treatment of acute respiratory distress syndrome (ARDS) and ventilator-associated pneumonia (VAP). AyuVis is a multi-asset, multi-indication biotech company.

​

Contact

To learn more about AyuVis’ innovative immunotherapies, please visit www.ayuvis.com or send an email inquiry to:

 

Sarah Wright
Sr. Operations Manager
sarah@ayuvis.com